Top new orphan molecular entities by U.S. sales in 2019
This statistic displays a projection of the top orphan molecular entities (approved in 2014) based on projected U.S. consensus sales in 2019. Biogen's Eloctate was approved in June 2014 and generated 58 million U.S. dollars in revenue during the same year in the United States. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.